GALT logo

GALT
Galectin Therapeutics Inc

10,441
Mkt Cap
$151.4M
Volume
201,612.00
52W High
$7.13
52W Low
$1.21
PE Ratio
-4.74
GALT Fundamentals
Price
$2.30
Prev Close
$2.43
Open
$2.43
50D MA
$2.87
Beta
0.58
Avg. Volume
347,149.38
EPS (Annual)
-$0.4847
P/B
-1.17
Rev/Employee
$0.00
$384.09
Loading...
Loading...
News
all
press releases
Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock?
Galectin Therapeutics (GALT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·8d ago
News Placeholder
More News
News Placeholder
FY2026 Earnings Estimate for GALT Issued By HC Wainwright
Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) - Research analysts at HC Wainwright lifted their FY2026 earnings estimates for shares of Galectin Therapeutics in a note issued to investors on...
MarketBeat·9d ago
News Placeholder
What is HC Wainwright's Estimate for GALT Q1 Earnings?
Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 EPS estimates for shares of Galectin Therapeutics in a note issued to investors on...
MarketBeat·10d ago
News Placeholder
Galectin Therapeutics (NASDAQ:GALT) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS
Galectin Therapeutics (NASDAQ:GALT - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.02...
MarketBeat·12d ago
News Placeholder
Galectin Therapeutics Inc. (NASDAQ:GALT) Short Interest Up 27.0% in March
Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) saw a large increase in short interest in the month of March. As of March 13th, there was short interest totaling 6,567,660 shares, an increase of 27.0% from the February 26th total of 5,169,383 shares. Currently, 21.5% of the company's...
MarketBeat·12d ago
News Placeholder
Galectin Therapeutics (GALT) Projected to Post Earnings on Monday
Galectin Therapeutics (NASDAQ:GALT) will be releasing its Q4 2025 earnings before the market opens on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-galectin-therapeutics-inc-stock...
MarketBeat·20d ago
News Placeholder
Galectin Therapeutics Highlights Belapectin Data in MASH Cirrhosis KOL Event, Eyes Next Steps
Galectin Therapeutics (NASDAQ:GALT) hosted a virtual key opinion leader (KOL) event to discuss belapectin as a potential treatment for patients with metabolic dysfunction-associated steatohepatitis...
MarketBeat·26d ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·3mo ago
News Placeholder
Galectin Therapeutics Inc. (NASDAQ:GALT) Short Interest Update
Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) was the target of a significant drop in short interest during the month of December. As of December 31st, there was short interest totaling...
MarketBeat·3mo ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·3mo ago
<
1
2
...
>

Latest GALT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.